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aggravated by the previous biopsy. The rate of pneumotho-
rax requiring chest tube following RFA was 21%. Local tumor 
control was achieved in 77% with a median follow-up of 12 
months. The morbidity of the CT-guided biopsy had no sta-
tistical impact on the local recurrence rate.  Conclusions: The 
simultaneous diagnostic and therapeutic approach includ-
ing CT-guided biopsy followed immediately by RFA of soli-
tary malignant pulmonary lesions is a safe procedure. The 
potential of this combined approach is to avoid unnecessary 
therapies and to perform adequate therapies based on his-
tology. Taking the local control rate into account, this ap-
proach should only be performed in those patients who are 
unable to undergo or who refuse surgery. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 In the general population, the prevalence of malignan-
cy in newly detected solitary pulmonary lesions (SPL) is 
approximately 60%  [1, 2] . In patients with a history of 
cancer, a rate of up to 90% malignancy in newly detected 
SPL has been reported  [3] . Currently, positron emission 
tomography (PET)  [4] is the most specific radio-diagnos-
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 Abstract 
 Background: In recent years experience has been accumu-
lated in percutaneous radiofrequency ablation (RFA) of lung 
malignancies in nonsurgical patients.  Objectives: In this 
study, we retrospectively evaluated a simultaneous diagnos-
tic and therapeutic approach including CT-guided biopsy 
followed immediately by RFA of solitary malignant pulmo-
nary lesions.  Methods: CT-guided transthoracic core needle 
biopsy of solitary pulmonary lesions suspicious for malig-
nancy was performed and histology was proven based on 
immediate frozen sections. RFA probes were placed into the 
pulmonary tumors under CT guidance and the ablation was 
performed subsequently. The procedure-related morbidity 
was analyzed. Follow-up included a CT scan and pulmonary 
function parameters.  Results: A total of 33 CT-guided biop-
sies and subsequent RFA within a single procedure were per-
formed. Morbidity of CT-guided biopsy included pulmonary 
hemorrhage (24%) and a mild pneumothorax (12%) without 
need for further interventions. The RFA procedure was not 
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tic tool, but false-positive results in nonmalignant pul-
monary lesions such as inflammatory lesions and granu-
lomatous diseases limit its clinical value  [5–7] . However, 
histologic proof of SPL should be standard prior to any 
treatment. Innovative endoscopic approaches (endobron-
chial ultrasound or navigation systems) can yield a histo-
logic diagnosis in up to 80% in SPL with a diameter of less 
than 30 mm  [8–10] . In many centers CT-guided biopsy is 
the diagnostic procedure of choice with expected diagno-
sis of malignancy for tumors greater than 1 cm over 90% 
 [11] . If both diagnostic tools fail to prove a diagnosis, sur-
gical resection is the preferred diagnostic and therapeutic 
approach in patients who are appropriate for surgery  [3, 
12] . In recent years, increasing experience has been gained 
in percutaneous radiofrequency ablation (RFA) as a min-
imal invasive technique in nonsurgical patients with 
promising oncological results and a tolerable morbidity 
related to the intervention  [13–15] . In this study, we ret-
rospectively evaluated a simultaneous diagnostic and 
therapeutic approach including CT-guided biopsy for 
histologic proof based on frozen sections, followed im-
mediately by RFA of solitary malignant pulmonary le-
sions in nonsurgical candidates.
 Methods 
 A total of 28 patients with the radiologic finding of an SPL that 
is suspicious for malignancy were included in this retrospective 
analysis. The median diameter of the SPL was 23 mm (range 10–
35 mm). Endoscopy, including endobronchial ultrasound, failed 
to provide proof of malignancy; PET-CT has shown a significant 
FDG uptake in the pulmonary nodule, whereas mediastinal and 
hilar lymph nodes lacked detectable FDG uptake. No cerebral me-
tastases were observed on contrast-enhanced cerebral MRI or CT. 
All subjects were introduced personally to a thoracic surgeon and 
inoperability was determined due to limited pulmonary function 
or other comorbidities ( table 1 ). Furthermore, all subjects were 
discussed in the interdisciplinary tumor board (thoracic surgeon, 
pulmonologist, medical oncologist, radiation oncologist, diag-
nostic and interventional radiologist, pathologist, anesthesiolo-
gist) and a minimally invasive interventional approach (CT-guid-
ed biopsy for proof of histology and subsequent therapeutic abla-
tion within a single procedure) was considered to be appropriate.
 Seven patients had a history of non-small cell lung cancer 
(NSCLC; lobectomy n = 1; radiotherapy due to limited pulmonary 
function n = 5; lobectomy + radiotherapy n = 1); 8 patients had a 
history of other malignancies (prostatic cancer n = 3; endometrial 
cancer n = 1; soft tissue sarcoma n = 2; oropharyngeal cancer n = 2).
 All patients underwent general anesthesia and endobronchial 
double-lumen intubation before lung biopsy. According to the le-
sion localization, the patient was placed in a supine or prone posi-
tion. Under CT guidance transthoracic core needle biopsy (Auto-
matic BARD  Magnum biopsy system MG 1522, BARD  coaxial 
needle 18G C1820B) was performed ( fig. 1 a). One tissue sample 
was immediately sent to the pathologist for immediate frozen sec-
tion and further samples were taken if needed for subsequent ad-
ditional diagnostics (immunochemistry or molecular pathology). 
Histology was proven based on immediate frozen section within 
approximately 10 min of the core-cut biopsy. If no malignancy 
was detected in the first sample, up to two further tissue samples 
were sent to the pathologist. The cannula of the biopsy system re-
mained in situ while awaiting the results of frozen section exam-
ination. If another biopsy was requested by the pathologist, it was 
taken via this cannula. After successful proof of malignancy, the 
cannula of the biopsy system was removed and a CT scan was 
performed for biopsy-related complications. The RFA probe was 
placed under CT guidance into the pulmonary tumor ( fig. 1 b). A 
limited pneumothorax, which was not progressive during the 
RFA procedure, was tolerated. Indication for chest tube place-
ment was progressive pneumothorax with consecutive aggrava-
tion of correct RFA probe placement or clinical symptoms of the 
patient.
 The technique of RFA depended on the tumor size according 
to the manufacturer’s recommendation. Bipolar RFA (Celon 
LABPower; single bipolar Celon  ProSurge RFA probe) was per-
formed using a single probe in tumors that were up to 2.0 cm in 
diameter, and multipolar RFA (Celon  LABPower; multiple bipo-
lar Celon  ProSurge RFA probes) was performed in tumors with 
a diameter ranging from 2.0 to 3.0 cm. Monopolar RFA (Boston 
Scientific  RF 3000; LeVeen 3-cm RFA probe) was performed in 
tumors with a diameter of  1 3 cm. After the application of the ap-
proved amount of thermal energy, the RFA probes were removed 
and a nonenhanced CT scan was performed to detect immediate 
complications. A chest radiograph was obtained 3 h later after 
extubation to assess the occurrence of complications, such as 
pneumothorax, hemothorax and pleural effusion. If a progressive 
pneumothorax was seen on the first chest radiograph, a chest tube 
was placed. If the pneumothorax was not progressive over time or 
a newly detected pneumothorax caused no symptoms, a second 
chest radiograph was performed 2 h later. A chest tube was placed 
if the patient was symptomatic or the pneumothorax was progres-
sive.
 Due to the patients’ comorbidity, all subjects were observed 
after the intervention for at least 24 h in the intensive care unit 
and underwent a nonenhanced follow-up CT scan the next day to 
document potential early adverse events.
Table 1. P atients were excluded from surgery due to the following 
comorbidities
Comorbidity n
Severely limited pulmonary function
(pred. FEV1 <40% or diffusion capacity <40%) 16
Severe cardiac risk (NYHA III, LVEF depression) 13
6-min walking test <150 m 12
Previous lung resection 6
Previous thoracic radiotherapy 4
Very limited ability of cooperation (ECOG >2) 5
Multiple comorbidities 18
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 Follow-up investigations at 1, 2 and 3 months after RFA and 
subsequently at 3-month intervals included clinical investigation, 
pulmonary function parameters (VC and FEV 1 ) and contrast-en-
hanced CT scan ( fig. 1 c,  2 d). In case of local progression the pa-
tient underwent PET-CT.
 Statistical analysis of the procedure-related morbidity was 
performed by Fisher’s exact test using GraphPad Prism statistical 
software (GraphPad Software, La Jolla, Calif., USA).
 The Ethics Committee of the University of Heidelberg ap-
proved this retrospective study (080/2006). The procedures to be 
undertaken were thoroughly explained to each subject and writ-
ten informed consent was obtained prior to the intervention.
 Results 
 During the 2-year period (November 2009 to October 
2011), a total of 28 subjects (20 male, 8 female; median age 
71 years, range 42–83) with the radiologic finding of a 
solitary pulmonary nodule underwent CT-guided biopsy 
with proof of malignancy based on the frozen section and 
subsequent RFA of the pulmonary lesion. A total of 5 sub-
jects underwent the procedure repeatedly (local recur-
rence on PET/CT in n = 3; new development of a contra-
a b
c
 Fig. 1.  a CT-guided core needle biopsy in a patient with severely 
limited pulmonary function (FEV 1 = 0.8 liters).  b Monopolar RFA 
after proof of histology (NSCLC).  c Follow-up CT scan 3 months 
after RFA: the ablated tumor tissue has shrunk in diameter. 
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lateral solitary pulmonary lesion in n = 2). Thus, a total 
of 33 CT-guided biopsies and subsequent RFA within a 
single procedure were performed in a total of 30 pulmo-
nary lesions (monopolar RFA n = 5, bipolar RFA n = 17, 
multipolar RFA n = 11). The median tumor diameter was 
2.3 cm (range 1.0–3.5 cm). The median duration of the 
RFA procedure was 45 min (range 19–92 min). The me-
dian duration of general anesthesia including patient po-
sitioning, CT-guided biopsy, immediate frozen section 
and placement of RFA probes was 135 min (range 60–225 
min). No complications related to general anesthesia were 
observed. The median stay in the intensive care unit after 
the intervention was 1 day (range 1–3 days).
 Malignancy was verified with CT-guided core cut bi-
opsy and immediate frozen section in all patients. In a 
total of 21 procedures, one tissue probe was sufficient for 
diagnosis, a second tissue probe was required in 8 cases 
and three tissue probes were necessary in 4 cases. In a to-
tal of 28 biopsies, frozen section verified NSCLC. Pulmo-
nary metastases were detected in a total of 4 patients with 
preexisting malignancies. Definite histology confirmed 
the result of the frozen section in a total of 32 biopsies 
(97%). In 1 patient with preexisting NSCLC, malignancy 
was detected based on the frozen sections; however, defi-
nite histology did not confirm this finding.
a b
c d
 Fig. 2.  a Baseline CT scan: pulmonary lesion with a diameter
of 2 cm.  b Parenchymal hemorrhage in the tumor-surrounding 
lung tissue developing during bipolar RFA.  c Control CT scan 1 
day subsequent to RFA: the parenchymal hemorrhage has mean-
while been mainly resorbed. The procedure related to mild and 
constant pneumothorax did not require drainage.  d Control CT 
scan 3 months subsequent to RFA: further contraction of the ab-
lated area indicates local tumor control. 
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 In a total of 8 patients (24%) hemorrhage in the tumor-
surrounding lung tissue was seen subsequent to core cut 
biopsy (mean tumor diameter 16 mm). A mild pneumo-
thorax requiring no drainage developed in a total of 4 
procedures (12%).
 The RFA probes were successfully placed at the 
planned position within the pulmonary tumors in all pa-
tients. Neither local hemorrhage nor pneumothorax ag-
gravated the correct probe placement. The appropriate 
amount of thermal energy was applied into the tumors. 
At the end of RFA, ground-glass parenchymal opacity 
surrounding the ablated tumors was observed in all pa-
tients.
 In a total of 3 patients (9%) pulmonary hemorrhage in 
the tumor-surrounding lung tissue was newly detected 
during RFA ( fig. 2 a, b). In a total of 7 patients (21%) pneu-
mothorax evolved during RFA. In a total of 3 patients 
(9%) pneumothorax was newly detected on the first chest 
radiograph after extubation ( fig.  2 c). Chest tube place-
ment was required in 1 patient (3%) during RFA to avoid 
a dislocation of the RFA probe. In a total of 6 patients 
(18%) a chest tube was placed subsequent to RFA due to a 
collapse of the lung. All chest tubes were removed with-
out further interventions after a median of 3 days (range: 
2–5 days).
 In a single subject, a pleural catheter was placed due to 
persisting pleural effusion for 4 days. One subject with a 
history of alcohol abuse and liver cirrhosis developed 
hemorrhage due to active bleeding at the ablation site. 
The concurrent hemothorax was evacuated, and the 
bleeding was stopped with surgical intervention via a 
mini-thoracotomy. Major and minor complications re-
lated to the RFA procedure are summarized in  table 2 . All 
patients were discharged in good clinical condition after 
a median of 6 days (range: 4–14 days); there was no 30-
day mortality.
 In a total of 8 patients with NSCLC (24%), local tumor 
recurrence was detected after a median follow-up period 
of 6 months based on an increase in the diameter of the 
ablated tumor tissue and high FDG uptake in PET-CT. 
Two subjects were not able to undergo repeated local ther-
apy – they received the best supportive care. One patient 
underwent stereotactic irradiation. Two patients with sys-
temic and local progression underwent systemic chemo-
therapy. Three patients were candidates for repeated RFA, 
and the PET-CT was also performed again. In the mar-
ginal zone of the initial ablation zone, a high FDG uptake 
was found. Consequentially, these patients underwent the 
repeated procedure. Unfortunately, local tumor control 
was achieved in only 1 of these patients. In the 2 remain-
ing patients, local and systemic tumor progression was 
observed during further follow-up. Altogether, local tu-
mor control was achieved in 23 lesions (77%) with a me-
dian follow-up of 12 months. The clinical course of the 
subjects included in this study is summarized in  figure 3 . 
 With regard to recurrence no statistically significant 
impact of biopsy-related hemorrhage [p = 1.0000; odds 
ratio (OR) = 1.056], biopsy-related pneumothorax (p = 
1.0000; OR = 1.048) and RFA-related pneumothorax (p = 
0.6518; OR = 0.4524) were found ( table 3 ).
 The pulmonary function parameters (VC and FEV 1 ), 
as measured at 1, 2 and 3 months after RFA, remained 
unchanged compared with the baseline values before 
RFA [median FEV 1 pre-RFA = 1.7 liter (56% pred. value); 
3 months post-RFA = 1.6 liter (54% pred. value)].
 Discussion 
 In this study, patients who were not candidates for sur-
gery because of their comorbidity underwent CT-guided 
biopsy and subsequent CT-guided RFA of a solitary pul-
monary lesion within a single session. To the best of our 
knowledge, this concurrent diagnostic and therapeutic 
approach has not been previously reported in the litera-
ture. The potential of this combined approach is to avoid 
unnecessary therapies and eventually perform adequate 
adjuvant therapies based on histology.
 With regard to the high-risk profile of our patients, we 
decided to perform this hybrid approach (including both 
biopsy and ablation) under general anesthesia for better 
patient comfort, better positioning during the procedure 
and better ability to address any intraprocedural compli-
Table 2. M orbidity related to CT-guided core needle biopsy and 
the RFA procedures
Morbidity Biopsy, n RFA, n
Pleural effusion
Requiring pleuracentesis
0 13 (39%)
1 (3%)
Pneumonia 0 2 (7%)
Pneumothorax
Requiring chest tube
4 (12%)
0
10 (30%)
7 (21%)
Local parenchymal hemorrhage 8 (24%) 3 (9%)
Hemothorax
Requiring mini-thoracotomy
0 1 (3%)
1 (3%)
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cations. Double-lumen intubation was chosen to protect 
the contralateral lung in case of local complications (e.g. 
hemorrhage). Since neither severe local hemorrhage nor 
significant pneumothorax were observed in our patients, 
we would agree that this approach may be seen as over-
protective. We are considering realizing this approach in 
local anesthesia in the future.
 CT-guided core needle biopsy was chosen to acquire a 
sufficient amount of tumor tissue to prove malignant di-
agnosis and be able to perform additional immunohisto-
chemistry and molecular pathological investigations as 
well (EGFR gene mutation analysis or EML4 ALK fusion 
genes)  [16] . In the literature the reported sensitivity of 
core needle biopsy ranges from 56 to 89%  [17] . In clinical 
practice 31–82% of pulmonary nodules are malignant 
 [18] ; however, the high rate of malignant histology in this 
series (all lesions were malignant) is clearly the result of 
the strict selection of our patients. The radiologic features 
of growth and high FDG uptake in PET-CT were clear 
hints for malignancy.
28 patients
CT-
guided
biopsy:
Pulmonary
metastasis
RFA
n = 4
RFA
n = 2
RFA
n = 24
Local
progression
RFA
n = 3
NSCLC
Tumor in contralateral
lung:
CT-
guided
biopsy:
NSCLC
CT-
guided
biopsy:
NSCLC
n = 8
n = 1 n = 2
n = 5
n = 2
n = 4 n = 16
n = 1 n = 2 n = 3 n = 3
Local control: n = 23
Systemic progression: n = 9
Local progression: n = 7
 Fig. 3. Clinical course of the patients included in the study. 
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 The rates of local hemorrhage and pneumothorax af-
ter core needle biopsy in this series are in line with the 
literature  [19, 20] . Both complications may potentially 
limit the optimal placement of the RFA probes in small 
pulmonary lesions and therefore may serve as main dis-
advantage of the proposed hybrid approach. In this se-
ries, however, RFA probe placement was not aggravated 
and complications in terms of hemorrhage or pneumo-
thorax had no significant impact on the local recurrence 
rate.
 Pneumothorax during or subsequent to RFA in this 
series was also in line with the reported rates in the lit-
erature  [14, 21] and had no impact on local recurrences as 
well. Furthermore, as a major complication, we observed 
a single hemothorax with the bleeding originating from 
the RF-probe insertion into the middle lobe. In the lit-
erature, hemothorax is infrequently reported  [22, 23] . 
Pleural effusions as the minor complication are frequent-
ly reported in the literature (up to 55%); however, only a 
few thoracenteses were needed, which is consistent with 
our findings  [24, 25] . An expeditious and effective man-
agement of potential complications is indispensable in 
this group of high-risk patients; therefore, it is critical that 
the interventions are performed by a team that is follow-
ing the patient very closely.
 Local tumor control was achieved with this hybrid ap-
proach in 23 (77%) patients. This rate is consistent with 
the local tumor control rate of RFA in the literature  [14] . 
Hypofractionated stereotactic radiotherapy – in stage I 
NSCLC resulting in up to 85% local tumor control and up 
to 5% therapy-associated grade 2 toxicity – currently ri-
vals RFA  [17, 26, 27] . Unfortunately, to date, no prospec-
tive randomized trial comparing RFA with stereotactic 
radiation therapy has been completed. However, future 
technical improvements in RFA have to focus on im-
proved local safety  [28] . The systemic progression rate af-
ter local tumor ablation in NSCLC is reported to be up to 
40% in the literature; in our series, distant metastases de-
veloped in 32% of the cases  [29] . A thorough search for 
possible metastases preceding the local ablation – in our 
patients, this was accomplished with PET and cerebral 
CT or MRI – is therefore indispensable when considering 
local tumor ablation.
 Given the risk profile of our patients and the duration 
of biopsy and frozen section examination, the need for 
mandatory histologic proof in all patients can be ques-
tioned. On the other hand, the potential of this com-
bined approach is to avoid unnecessary therapies, e.g. in 
benign diseases (also with positive PET), and eventually to 
perform adequate subsequent adjuvant therapies based on 
histology. In high-risk patients without anticipated benefit 
of histology, RFA might be performed without histologic 
proof of malignancy based on the above-mentioned radio-
logical criteria or due to clinical history  [30, 31] .
 Conclusion 
 Simultaneous CT-guided biopsy and RFA of solitary 
pulmonary lesions in high-risk patients is a safe proce-
dure. The potential of this combined approach is to ob-
tain a certain diagnosis, to avoid unnecessary therapies 
 Table 3. R elationship between compli cating factors (pneumothorax of hemorrhage) secondary to CT-guided 
core  needle biopsy (CNB) or RFA and local  recurrence of tumor
G roups Strength of association
recurrence
of tumor, n
no recurrence
n
Pneumothorax due to CNB 1 3 p = 1.000
No pneumothorax 7 22 OR = 1.048
95% CI = 0.093–11.760
Hemorrhage due to CNB 2 6 p = 1.000
No hemorrhage 6 19 OR = 1.056
95% CI = 0.167–6.682
Pneumothorax due to RFA 1 6 p = 0.652
No pneumothorax 7 19 OR = 0.452
95% CI = 0.046–4.459
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and eventually to perform adequate therapies based on 
histology. Taking the local progression rate into account, 
RFA should only be performed in those patients who are 
unable to or refuse to undergo surgery.
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